COMPARING THE POTENTIAL BUDGET IMPACT OF NOVEL THERAPIES FOR ADVANCED MELANOMA IN SECOND-LINE UNDER BRAZILIAN PRIVATE HEALTH CARE SYSTEM PERSPECTIVE

被引：0

作者：

Tsuchiya, C. T. ^{[1
]}

Buschinelli, C. T. ^{[1
]}

Tobaruella, F. S. ^{[1
]}

Maximo, M. F. M. ^{[1
]}

Guzzo, M. R. ^{[1
]}

Goncalves, T. M. ^{[1
]}

机构：

[1] Roche Brazil, Sao Paulo, Brazil

来源：

VALUE IN HEALTH | 2013年 / 16卷 / 07期

关键词：

D O I：

10.1016/j.jval.2013.08.2021

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：A683 / A683

页数：1

共 47 条

[21] CARFILZOMIB/LENALIDOMIDE/DEXAMETHASONE IN THE SECOND-LINE SETTING FOLLOWED BY DARATUMUMAB/LENALIDOMIDE/DEXAMETHASONE IN THE THIRD-LINE SETTING VERSUS THE OPPOSITE TREATMENT SEQUENCE: A COST COMPARISON STUDY FROM A BRAZILIAN PRIVATE HEALTH CARE PERSPECTIVE
Tanaka, S.
Coggia, A.
Arancibia, A.
Majer, I. M.
Aratangy, G.
VALUE IN HEALTH, 2019, 22 : S479 - S479
[22] BUDGET IMPACT ANALYSIS OF ABIRATERONE ACETATE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PREVIOUSLY TREATED WITH DOCETAXEL FROM THE PERSPECTIVE OF THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM
Vitale, V.
Asano, E.
Pereira, M. L.
VALUE IN HEALTH, 2013, 16 (07) : A665 - A665
[23] Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective
Thongprasert, Sumitra
Tinmanee, Sirana
Permsuwan, Unchalee
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2012, 8 (01) : 53 - 61
[24] Cost-effectiveness of new therapies in first-line treatment of advanced melanoma for patients with independent BRAF mutation status from a Brazilian private payer perspective.
Matteucci, Christina
Lima, Joao P. S. D. N.
Bernardino, Graziela
Oliveira, Ana Paula
Maia, Daniela Galdeano
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[25] COST-EFFECTIVENESS ANALYSIS OF SORAFENIB ASSOCIATED TO BEST SUPPORTIVE CARE (BSC) VERSUS BEST SUPPORTIVE CARE ALONE IN THE SECOND LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE
Teich, V
Fernandes, R. A.
Schiola, A.
VALUE IN HEALTH, 2009, 12 (03) : A42 - A42
[26] ESTIMATING THE BUDGET IMPACT IN BRAZILIAN PUBLIC HEALTH CARE SYSTEM OF TOCILIZUMAB REIMBURSEMENT AS A RHEUMATOID ARTHRITIS FIRST-LINE BIOLOGICAL THERAPY
Tsuchiya, C. T.
Tobaruella, F. S.
Ramos, L. A.
Buschinelli, C. T.
Maximo, M. F. M.
Goncalves, T. M.
VALUE IN HEALTH, 2013, 16 (07) : A715 - A715
[27] BUDGET IMPACT ANALYSIS OF SAXAGLIPTIN FOR THE TREATMENT OF DIABETES MELLITUS TYPE 2 (T2D) PATIENTS IN THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM
Barbosa, E.
Ribeiro, E.
Asano, E.
Nita, M.
Rached, R.
Mantilla, P.
Pimentel, A.
Donato, B. M.
Rahal, E.
VALUE IN HEALTH, 2010, 13 (03) : A56 - A57
[28] BUDGET IMPACT ANALYSIS OF 5% LIDOCAINE MEDICATED PLASTER COMPARED WITH PREGABALIN OR GABAPENTIN MONOTHERAPY FOR THE TREATMENT OF DIABETIC POLYNEUROPATHY UNDER THE PERSPECTIVE OF BRAZILIAN PRIVATE HEALTHCARE SYSTEM
Piedade, A. D.
Kashiura, D.
Engel, T.
Rodrigues, C. R.
VALUE IN HEALTH, 2017, 20 (05) : A214 - A214
[29] BUDGET IMPACT MODEL (BIM) OF RIVAROXABAN IN COMPARISON WITH ENOXAPARIN PLUS WARFARIN IN THE TREATMENT OF VENOUS THROMBOEMBOLISM (VTE) UNDER THE PERSPECTIVE OF THE PRIVATE HEALTH SYSTEM
Piedade, A.
Paladini, L.
Tobaruella, F.
Nakada, C.
VALUE IN HEALTH, 2015, 18 (07) : A383 - A384
[30] Cost Utility of Target Therapies Compared to Dacarbazine for First-Line Treatment of Advanced Non-Surgical and Metastatic Melanoma in the Brazilian National Health System
Guerra, Renata Leborato
Correa, Flavia de Miranda
Alves Fernandes, Ricardo Ribeiro
Zimmerman, Ivan Ricardo
VALUE IN HEALTH REGIONAL ISSUES, 2019, 20 : 103 - 109

← 1 2 3 4 5 →